News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (Intranasal Diazepam)


6/23/2011 5:54:57 AM

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study. The propriety formulation was designed and manufactured at Particle Sciences. In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for DiastatĀ® (rectal diazepam gel), the only FDA approved therapeutic product for home treatment of acute repetitive seizures. The bioavailability of the NRL-1 intranasal formulation was 96%.

According to Dr. Robert Lee, Particle Sciences VP of Pharmaceutical Development, "We are obviously very pleased with the results Neurelis have obtained. It has been a pleasure working with them and very rewarding to contribute to a product that should truly improve the quality of life for patients with acute repetitive seizures and their caregivers. We were able to achieve extremely high levels of solubilized diazepam using our DOSEĀ® platform that combines empirically obtained data with customized solubility software. This approach along with Particle Sciences' cGMP analytical and manufacturing services have enabled our clients to more rapidly advance to the clinic with commercially viable formulations."

David F. Hale, Chairman of Neurelis, said that "The team at Neurelis was very pleased with the work on the formulation conducted by Particle Sciences. They really focused on a key issue with diazepam which is solubility and developed two proprietary formulations which we evaluated in the clinical trial. Based on the results obtained in the clinical trial we plan to move ahead with the further development of this product candidate for patients with epilepsy who have acute repetitive seizures."

Particle Sciences Inc. is an integrated provider of drug development services. Particle Sciences utilizes a broad suite of drug delivery technologies to address a diverse range of challenges. With special expertise in solubility, particulate based formulations and drug/device combination products, Particle Sciences has become a leader in drug delivery development. Through a full range of formulation, analytic, bioanalytic, and sterile and non-sterile manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market. Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: Maureen Cochran
mcochran@particlesciences.com
610-861-4701

SOURCE Particle Sciences Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES